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Abstract The rodent protoparvovirus H-1PV, with its
oncolytic and oncosuppressive properties, is a promising an-
ticancer agent currently under testing in clinical trials. This
explains the current demand for a scalable, good manufactur-
ing practice-compatible virus purification process yielding
high-grade pure infectious particles and overcoming the lim-
itations of the current system based on density gradient cen-
trifugation. We describe here a scalable process offering high
purity and recovery. Taking advantage of the isoelectric point
difference between full and empty particles, it eliminates most
empty particles. Full particles have a significantly higher cat-
ionic charge than empty ones, with an isoelectric point of 5.8–
6.2 versus 6.3 (as determined by isoelectric focusing and
chromatofocusing). Thanks to this difference, infectious full
particles can be separated from empty particles and most pro-
tein impurities by Convective interaction media®
diethylaminoethyl (DEAE) anion exchange chromatography:
applying unpurified H-1PV to the column in 0.15 M NaCl
leaves, the former on the column and the latter in the flow
through. The full particles are then recovered by elution with
0.25 M NaCl. The whole large-scale purification process in-
volves filtration, single-step DEAE anion exchange chroma-
tography, buffer exchange by cross-flow filtration, and final
formulation in Visipaque/Ringer solution. It results in 98%
contaminating protein removal and 96% empty particle elim-
ination. The final infectious particle concentration reaches
3.5E10 plaque forming units (PFU)/ml, with a specific activity
of 6.8E11 PFU/mg protein. Overall recovery is over 40%. The
newly established method is suitable for use in commercial
production.
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Introduction
Parvovirus H-1 (H-1PV) belongs to the family Parvoviridae
(Cotmore et al. 2014). It consists of a non-enveloped icosahe-
dral capsid 25 nm in diameter, containing a linear ~5 kb
single-stranded DNA genome. The viral DNA encodes non-
structural proteins—notably NS1 (83 kDa) and NS2
(25 kDa)—and the capsid proteins VP1 (81 kDa) and VP2
(65 kDa). VP3 (63 kDa), another capsid protein, results from
posttranslational cleavage of VP2, which takes place only in
full particles (Faisst et al. 1995; Halder et al. 2012; Hanson
and Rhode 1991). Although H-1PV is a rodent virus, it can
infect and replicate in cells of a variety of vertebrates, includ-
ing humans, and is known to exhibit oncolytic and
oncosuppressive properties in a number of tumor models
(Nuesch et al. 2012; Rommelaere et al. 2010). As a result of
promising preclinical studies, the first in-man phase I/IIa clin-
ical trial of H-1PV was conducted in 2011–2015 in patients
with recurrent glioblastoma (Geletneky et al. 2012). At the
moment, a second phase I/II clinical trial has been initiated
in patients with inoperable metastatic pancreatic cancer
(ClinicalTrials.gov Identifier: NCT02653313; manuscript in
preparation).
For these trials, the H-1PV good manufacturing practice
(GMP) batches were purified by density gradient centrifuga-
tion (Leuchs et al. 2016; Ungerechts et al. 2016); however,
this method is limited in scale. Upscaling is needed for the
next clinical trial phases. It is therefore necessary to establish a
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simple, efficient, robust, reproducible, and scalable
chromatography-based purification process allowing elimina-
tion of empty capsids and protein impurities in one step, while
promoting high recovery of infectious particles. Furthermore,
purified H-1PV has ultimately to be formulated into Visipaque
(48% iodixanol in Ringer solution), where the virus has
known stability and which is also an X-ray contrast reagent
for drug visualization in the human body.
We describe here a scalable, reproducible, high-grade chro-
matography-based procedure for H-1PV purification. An im-
portant challenge is to eliminate empty particles which were
assembled but in which viral DNA failed to be packaged. The
known difficulty of separating empty from full (genome-
containing) particles by chromatography prompted us to first
determine the isoelectric point difference between empty and
full particles. In a second step, we exploited this difference to
eliminate empty particles as well as protein contaminants by
anion exchange chromatography, thus obtaining highly pure
batches of infectious particles. Convective interaction media
(CIM®)diethylaminoethyl (DEAE) monolith columns were
used, as they achieve convective mass transport resulting in a
high flow rate, yield, and efficiency. They also capture large
molecules or particles such as H-1PV. What is more, these
columns do not lose resolut ion upon upscal ing
(Rajamanickam et al. 2015).
Materials and methods
Preparation of clarified H-1PV cell lysate
H-1PV wild-type (wt) virus was produced in a 10-layer
CellSTACK® (CS; Corning, Wiesbaden, Germany) accord-
ing to Leuchs et al. 2016. For this, NB-324K cells were seeded
at 3.6E4 cells/cm2 and infected immediately with H-1PV wt
(Kestler et al. 1999) at a multiplicity of infection (MOI) of
0.01 plaque forming units (PFU) per cell. To generate the
clarified cell lysate, the cells were harvested after 4 days of
incubation, lysed in 50 mM Tris-HCl (Trizma® hydrochlo-
ride; Sigma-Aldrich Co, St. Louis, USA) buffer, DNAse-
treated (50 U/ml, Sigma-Aldrich Chemie GmbH, Steinheim,
Germany), and filtered through 0.2- and 0.1-μm membranes
(Sartorius AG, Göttingen, Germany).
The H-1PV is also publically available at ATCC® VR-356.
Purification of H-1PV
IOD-PBS and VIS-Ringer density gradients
Iodixanol-PBS (IOD-PBS) and Visipaque-Ringer (VIS-
Ringer) density gradient purifications were performed accord-
ing to Leuchs et al. 2016 with 20 ml clarified cell lysate.
CsCl density gradient
CsCl density gradient purificationwas performed according to
Leuchs et al. 2016.
Small- and large-scale DEAE anion exchange
chromatography (AEX)
All chromatographic studies were performed with a 0.34-ml
CIM® DEAE monolith disk or an 8-ml CIM® DEAE mono-
lith column (1.3 μm pore size; Bia Separations, Ajdovscina,
Slovenia) and ÄKTAprime (GE Healthcare Europe GmbH,
Freiburg, Germany) at room temperature (RT) under laminar
flow. The CIM® monolith is a single homogeneous piece cast
from methacrylate polymers containing flow through pores.
DEAE is a weak anion exchanger with a charged
diethylamino group which selectively binds molecules with
a predominant negative charge. The flow rate of the mobile
phase was 0.7 or 2 ml/min depending on the column size.
Absorbance was monitored at 280 nm and is expressed in
milli absorbance units (mAu). Conductivity is expressed in
millisiemens (mS). All buffers and the sample were filtered
through 0.2-μm filters. The column was equilibrated with the
application buffer prior to the start of each run, until constant
conductivity and UV absorbance values were observed.
Elution steps were followed by a high-salt wash with 1 M
NaCl (Sigma-Aldrich Chemie GmbH, Steinheim, Germany).
The application buffer was 50 mM Tris-HCl or 0.15 M NaCl
in 50 mM Tris-HCl, adjusted to pH 8.7. The sample was
diluted in application buffer and applied to the column. This
was followed by a wash with application buffer until baseline
UV absorbance was reached. Elution was performed with a
continuous salt gradient from 0 to 0.5 M NaCl in 50 mM Tris-
HCl pH 8.7 or from 0.15 to 0.4M (0.3M for large scale) NaCl
in 50 mM Tris-HCl pH 8.7. One-milliliter fractions were col-
lected during the runs and analyzed for genome-containing
particles (GP), physical particles (PP), and plaque forming
units. Because plaque forming unit evaluation is a laborious
cell-based method, it was done only in large-scale chromato-
graphic experiments and for analysis of the final formulation,
given the importance of the infectious virus titer in anticancer
virotherapy.
Formulation of purified H-1PV after the preparative
DEAE column
The H-1PVeluate from the DEAE column contained 0.25 M
NaCl. To eliminate salt and formulate into Visipaque (48%
iodixanol in Ringer), it was necessary to perform buffer ex-
change into Ringer solution (AlleMan Pharma GmbH,
Reutlingen, Germany) followed by formulation in Visipaque
(48% iodixanol in Ringer).
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For buffer exchange into Ringer solution, two approaches
were used:
On the one hand, a 5-ml HiTrap™ desalting column
(GE Healthcare Europe GmbH, Freiburg, Germany) was
used with the ÄKTAprime system. HiTrap™ utilizes
cross-linked dextran for size exclusion chromatography.
The column was equilibrated first with five column vol-
umes (CV) of Ringer solution. Then, the sample was
injected into a 5-ml sample loop filled with Ringer solu-
tion, loaded onto the column, and eluted with two CV of
Ringer solution. One-milliliter fractions were collected and
analyzed for genome-containing particles and physical par-
ticles. On the other hand, 6 ml Vivaspin® concentrators
(cutoff 30 kDa; Sartorius AG, Göttingen, Germany) were
used. The membrane ultrafiltration system was first steril-
ized with 70% ethanol for 20 min, centrifuged at 3000×g,
rinsed with 6 ml sterile water for injection use, centrifuged
again, and allowed to dry under laminar flow. Samples
with a starting volume of about 1 ml were pipetted into
the concentrator, diluted 1:5 with Ringer solution, and cen-
trifuged at 3000×g until the volume reached 1 ml. Samples
with a starting volume of 2 ml or more were first concen-
trated to 1 ml and then diluted with Ringer solution. This
was done three times so as to dilute the initial buffer 1:125
in Ringer solution. The last concentration step was carried
out down to a sample volume of ~300 μl. The refraction
index of the sample was then measured with a digital re-
fractometer AR200 (Reichert, Inc., Depew, NY, USA) and
had to be that of Ringer solution (1.3342 ± 0.0002).
The samples in Ringer solution obtained by one of the
above methods were mixed with Visipaque™ 320 (contains
65.2% iodixanol; GE Healthcare Europe GmbH, Freiburg,
Germany) to 48% iodixanol final concentration. The refrac-
tion index of the sample was then measured and had to be that
of a 48% Visipaque solution (1.41 ± 0.005).
Quantification and qualification of H-1PV batches
Virus quantification and characterization were done by a
plaque formation assay (for infectious particles), qPCR (for
GP), H-1PV Capsid-ELISA (for PP), protein quantification
and sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) with silver staining, western blotting, and sterility
assessment (see Leuchs et al. 2016 for method description).
Electron microscopy
Electron microscopic analysis of the purified virus batches
was performed according to Leuchs et al. 2016 with a few
minor modifications. A preincubation step with 0.05% BSA
solution for 1 min was added before sample incubation as well
as a virus deactivation step with 0.1% glutaraldehyde for
5 min after sample incubation. Photos were taken with a
Zeiss EM 900 transmission electron microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany) at 85,000×
magnification.
Determination of H-1PV pI
Isoelectric focusing
Full and empty viral capsid preparations (CsCl density
gradient purified) were separated in the electric field on
the basis of their different isoelectric points (pI values).
All materials used for isoelectric focusing were purchased
from Serva Electrophoresis GmbH, Heidelberg, Germany.
The 0.9% agarose gels were cast on a GelBond film with
added 2.5% Servalyt carrier ampholytes pH 5–8 forming a
pH gradient in an electric field. Gel electrophoresis was per-
formed with the electrophoresis power supply EPS 3500 XL
(Amersham Pharmacia Biotech Europe GmbH, Freiburg im
Breisgau, Germany) under laminar flow. The system was
cooled to 10 °C, and the cooling reagent Bayol F was applied
to the ceramic cooling plate between the gel and the plate.
Filter paper strips soaked in electrode solutions were applied
between the gel and the electrodes to maintain a stable gradi-
ent. An acidic solution was used at the anode and a basic one
at the cathode. A 10-μl sample was placed on the gel surface
by means of a silicon applicator strip with sample holes, laid
on the gel surface. Separation conditions were as follows:
isoelectric focusing of the sample at 250 V, 10 mA, 10 W
for 10 min; 500 V, 10 mA, 10 W for 20 min; and 1000 V,
10 mA, 10 W for 40 min. Fixation and silver staining were
performed according to Willoughby and Lambert 1983.
Chromatofocusing
Chromatofocusing is a protein separation technique in which
proteins elute from the column according to their pI.
Chromatofocusing of empty and full capsid virus preparations
(CsCl density gradient purified) was done at RT under laminar
flow with a Mono P 5/50 column (GE Healthcare Europe
GmbH, Freiburg, Germany) and an ÄKTAprime equipped
with a 500-μl injection loop. Mono P is a weak anion ex-
changer charged with mixed quaternary and tertiary amines.
The flow rate of the mobile phase was 0.7 ml/min. The absor-
bance was monitored at 280 nm. All buffers and the sample
were filtered through 0.2-μm filters. The application buffer
was 0.025 M triethanolamine (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) adjusted to pH 8.3 (for full
and empty preparations) or 9.5 (for unpurified cell lysate) with
concentrated iminodiacetic acid (Santa Cruz Biotechnology,
Dallas, USA). The elution buffer consisted of Polybuffer 96
and Polybuffer 74 (GE Healthcare Europe GmbH, Freiburg,
Germany) was diluted according the manual’s instruction in
water for injection use, and the pHwas adjusted to 5.0 (for full
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and empty preparations) or 3.5 (for unpurified cell lysate) with
concentrated iminodiacetic acid. The descending linear pH
gradients (pH 8 to 5 for full and empty particle preparations
and pH 9.4 to 3.5 for unpurified cell lysate) were obtained
according to Mono P 5/50 manufacturer’s instructions. For
this, the column was equilibrated with application buffer at a
pH slightly above the highest pH required. The elution buffer
(adjusted to the lowest pH required) was passed through the
column to generate first a pre-gradient. This was followed by
application of the sample diluted in application buffer. Further
application of the elution buffer to the column resulted in a
moving descending pH gradient. This elution procedure led to
formation of a pH gradient from pH 8.0 to 5.0 or from 9.4 to
3.5 with aΔ pH of 0.1–0.3 between fractions. Fractions of 0.5
or 1 ml were collected and analyzed for GP and PP. The pH of
the collected fractions was measured manually with a Mettler
Toledo InLab Viscous Pro pH electrode.
Results
The aim of this study was to develop a purification process
allowing separation of empty particles from particles contain-
ing a full genome and compatible with large-scale H-1PV
production for clinical applications.
Isoelectric point of H-1PV and process impurities
In order to separate empty from full H-1PV wt viral particles,
it was necessary to find an exploitable difference in their phys-
ical properties. Isoelectric focusing was performed on purified
empty and full particle preparations to determine the respec-
tive isoelectric points of these particles. The results (Fig. 1)
revealed a pI of 6.3 for empty particles and of 5.8–6.2 for full
particles (with negligible contamination by empty capsids). To
see if this pI difference might be exploited in purifying infec-
tious virus (i.e., to eliminate empty particles and contaminat-
ing proteins), chromatofocusing was used. First, CsCl-
purified empty or full particle preparations were loaded onto
a Mono P 5/50 column and eluted as described under
BMaterials and methods^. By this procedure (Fig. 2a),
chromatofocusing identified a pI of 6.3 for empty particles
(PP-to-GP ratio ~869; data not shown) and of 5.8–6.1 for full
particles (PP-to-GP ratio ~1; data not shown), thus confirming
the results obtained by isoelectric focusing. Furthermore,
chromatofocusing was used to estimate the pI range of impu-
rities (host cell proteins, FBS) present in the clarified cell
lysate. A significant amount of impurities were eluted from
the Mono P column at basic pH (pI range 9.4 to 7). The PP-to-
GP ratio was 43 at pH 6.4 versus 13 at near pH 5.7, in keeping
with the pI values determined for empty and full particles.
Small-scale anion exchange (AEX) chromatography
for determining optimal buffer and salt conditions
The isoelectric points of proteins correlate with the charge at
which they bind to/elute from the chromatography column. As
the salt concentration increases, proteins with the weakest ion-
ic interactions elute from the column first. With knowledge of
the pI values of empty and full H-1PV particles and of the
impurities arising during production, it is possible to separate
these entities by AEX chromatography: most protein impuri-
ties should be eluted first, followed by empty particles and
finally full particles.
As equilibration buffer for the AEX chromatography,
50 mM Tris-HCl pH 8.7 was chosen for its compatibility with
virus harvest. For optimal binding, in theory, the pH of the
buffer has to be at least 1–2 pH units above the pI of the
protein (Fekete et al. 2015). At pH 8.7, the impurities should
not bind, as they are weakly negatively charged, neutral, or
even positively charged (pI between pH 9.5 and 7.0). Since
the pI is 6.3 for H-1PV empty particles and 5.8–6.1 for full
particles, the virus is negatively charged at pH 8.7.
Preliminary studies performed with different ion exchange
columns to determine binding and elution conditions (data
not shown) demonstrated that a weak anion exchanger










M        1        2         3       4pH
full empty
Fig. 1 Determination of the isoelectric points of H-1PV wt empty and
full capsids by isoelectric focusing. Two independently purified batches
of empty or full capsids were loaded on the 0.9% agarose gel and focused
in the electric field according to their respective pI values. The bands were
visualized by silver staining. M indicates Biorad markers pH 4.45–9.6,
lane 1 indicates full particles from batch 1, lane 2 indicates empty
particles from batch 1, lane 3 indicates full particles from batch 2, and
lane 4 indicates empty particles from batch 2
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CIM® DEAE monolith column with a 1.3 μm pore size was
chosen for the chromatographic studies because of its ability
to accommodate large molecules specifically while maintain-
ing good mechanical stability.
Sodium chloride, sodium acetate, and ammonium acetate
were tested to determine the best salt for elution. A mixture of
pre-purified empty and full particles was applied to a 0.34-ml
CIM® DEAE monolith disk and eluted with a continuous 0–
0.5 M gradient of the tested salt in 50 mM Tris-HCl pH 8.7.
The peak fractions were analyzed for their PP and GP content.
All elution profiles displayed two UVabsorbance peaks: one
corresponding to empty particles followed by one correspond-
ing to full particles. As all the salts tested proved suitable for
separating empty from full particles, we chose to continue
working with NaCl because H-1PV is stable in NaCl solution
(data not shown) and because NaCl is present in the desired
final Visipaque/Ringer formulation (0.053 M NaCl). When a
continuous gradient of NaCl was applied (0–0.5 M NaCl in
50 mM Tris-HCl pH 8.7), the empty particles were eluted at
0.13–0.15 M NaCl (PP-to-GP ratio ~300) and full particles at
0.2–0.25 M NaCl (PP-to-GP ratio ~1) (Fig. 3a). As these salt
concentrations could not be measured directly, the corre-
sponding conductivity values were also measured (18–22
mS for empty particles and over 25 mS for full particles) to
ensure a reproducible purification process in further develop-
ment experiments.
In a subsequent experiment, a small amount of clarified
H-1PV harvest was prepared in 50 mM Tris-HCl pH 8.7 with
0.15 M NaCl and loaded onto the 0.34-ml CIM® DEAE
monolith disk to allow flow through of empty particles as well
as impurities and binding of full particles to the column. The
disk was then eluted with a 0.15–0.4 M NaCl gradient. As
shown in the chromatogram of Fig. 3b, about 70% of the
empty particles and 60% of the protein impurities were elim-
inated in the flow through and wash (first UV peak), whereas
about 60% of the full particles were eluted near 0.25 M NaCl
(second UV peak).
Reproduced large-scale single step AEX chromatography
After determination of the optimal buffer and salt conditions, a
large-scale purification was performed with clarified cell ly-
sate from 2.3E8 cells (corresponding to the production of one
10-layer CS). Clarified cell lysate diluted in 50 mM Tris-HCl
pH 8.7 containing 0.15 M NaCl was loaded onto an 8-ml
CIM® DEAE monolith column and eluted with a continuous
salt gradient (0.15–0.3 M NaCl in 50 mM Tris-HCl pH 8.7).
As seen in Fig. 4, empty particles were eluted in the flow
through and wash (first UV peak) (PP-to-GP ratio near 50.0;
2.3E14 total PP). Full particles were eluted at 0.2–0.25 M
NaCl (conductivity 26–31.8 mS, second UV peak). The virus
concentration was approximately 1E13GP/ml and 1E10 PFU/
ml (data not shown) and the PP-to-GP ratio was about 1.
Chromatographic purification of clarified H-1PV cell ly-
sate was reproduced for five individual batches. These exper-
iments revealed elimination of 67 ± 21% protein impurities
and 65 ± 28% empty particles, with recovery of 72 ± 13% GP
and 49 ± 13% PFU (Table 1). The salt concentration required
for full infectious particles was 0.2–0.25 M NaCl, with a con-
ductivity of 25–31.8 mS. Taken together, these results show
that for the final formulation, it should be possible, in the
future, to collect only one fraction, corresponding to this con-
ductivity range.
Buffer exchange and final formulation after AEX
chromatography
For the final formulation in Visipaque/Ringer solution, the full
particle eluate from the DEAE column had first to be buffer-




Fig. 2 pI profiles of empty and full H-1PV capsids (a) and impurities (b),
obtained by chromatofocusing with a Mono P 5/50 column. The fractions
were analyzed for genome-containing particles (GP), physical particles
(PP), and protein content (protein impurities). a The isoelectric point of
empty capsid particles is at pH 6.3, as depicted by the physical particle
peak and as evidenced by the PP-to-GP ratio (not shown): ratio ~869 at
the pH corresponding to the PP peak. The isoelectric point of full capsid
particles was around pH 5.6-6.1. The PP-to-GP ratio (not shown) was
near 1 in this pH range. b The impurities in the clarified cell lysate (host
cell proteins, FBS) showed isoelectric points between pH 9.5 and 7.0,
eluting from the Mono P column before pH 7.0
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Visipaque to obtain a refraction index of 1.41 ± 0.05, corre-
sponding to 48% iodixanol. Two buffer exchange methods
were tested: use of a HiTrap™ desalting column and use of
Vivaspin® concentrators. Each method was applied twice.
The results were compared with those obtained by the stan-
dard purification method (density gradient centrifugation in
IOD-PBS followed by VIS-Ringer) applied to the same virus
harvest batch. Table 2 summarizes the results. With the newly
developed chromatographic purification method, a prepara-
tion containing only full particles was obtained (PP-to-GP
ratio ~1). PFU recovery was at least twice as high (around
40%) as with the standard method, and the specific activity
was similar (or even higher after Vivaspin® cross-flow filtra-
tion). The infectious virus titer obtained either by the standard
method or by DEAE chromatography with Vivaspin® filtra-
tion was about 3E10 PFU/ml; after DEAE chromatography
and HiTrap™ desalting, it was 3E9 PFU/ml. The three
methods reduced protein impurities with equal effectiveness
(>96%), but chromatographic purification followed by either
buffer exchange procedure eliminated empty particles more
effectively (>95%) than the standard method (85%). Virus
purity, as determined by SDS-PAGE with silver staining,
was the same after all three procedures (Fig. 5). Electron mi-
crographs of the preparations obtained by the novel strategy
ml


























Fig. 3 Optimal buffer and salt conditions for DEAE chromatography. a
Pre-purified empty and full H-1PV particles in 50 mM Tris-HCl pH 8.7
were applied to the DEAE column and eluted with a continuous 0–0.5 M
NaCl gradient. The elution profile shows the elution of empty capsid
particles in fraction 8 (first UV absorbance peak) with 0.15 M NaCl
(conductivity 22 mS). The second UV absorbance peak, starting at
fraction 11, shows desorption of full capsid particles at 0.2–0.25 M
NaCl (conductivity 29–32 mS). Physical particles (PP) and genome-
containing particles (GP) were quantitated. b Clarified cell lysate was
diluted in 50 mM Tris-HCl pH 8.7 containing 0.15 M NaCl and applied
to the DEAE column. Empty particles were recovered in the flow through
and in the 0.15 M wash (first UVabsorbance peak). Upon elution with a
0.15–0.4 M NaCl gradient, full particles were eluted near 0.25 M NaCl
(second UV absorbance peak). Physical particles (PP) and genome-
containing particles (GP) were quantitated
0.15M NaCl 0.15-0.3 M NaCl
empty fullFig. 4 Large-scale
chromatography of a 2.3E8 cell
harvest (corresponding to one 10-
layer CellSTACK®, reproduced
five times). When clarified cell
lysate diluted in 50 mM Tris-HCl
pH 8.7 containing 0.15 M NaCl
was loaded onto the 8-ml DEAE
column, empty capsids was eluted
in the flow through and wash
(first UV peak). Full capsids was
eluted in fractions 1–5 at NaCl
concentration 0.25 M during
elution with a continuous 0.15–
0.3 M NaCl gradient (second UV
peak, PP/GP ratio ~1)
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showed full particles predominantly, in contrast to standard
preparations. The flow diagram in Fig. 6 summarizes the
downstream process steps of all three methods. Quality con-
trol tests demonstrated that all final formulated batches were
sterile.
Discussion
In this study, we have developed a simple, scalable high-grade
purification method for H-1PV. Empty particles are an unde-
sirable by-product of H-1PV production, liable to cause an
immune response without efficacy (Gao et al. 2014).
Although ultracentrifugation-based methods have been used
successfully to eliminate empty particles (Halder et al. 2012;
Leuchs et al. 2016), these procedures are not scalable, they are
only semi-sterile, and fractionation is less controllable than
with chromatographic methods. This explains why it was ur-
gent to develop new purification approaches suitable for
upscaling.
As a basis for chromatographic purification, we first deter-
mined the pI values of empty and full particles: 6.3 and 5.8–
6.1, respectively. Isoelectric focusing and chromatofocusing
gave similar results. For full particles, only a pI range could be
obtained due to possible defective interfering virus particles
(Faust and Ward 1979). Similar theoretical pI values were
calculated for adeno-associated virus serotype 1 (pI, 6.3 for
empty particles and 5.9 for full particles) (Venkatakrishnan
et al. 2013). Knowledge of the isoelectric points of empty
and full H-1PV was essential to developing the purification
procedure and might have implications for virus interactions,
stability, production, and in vitro studies (Xia 2007).
We have tested the ability of different chromatographic
systems to eliminate empty particles and impurities.
Unexpectedly, Capto Core 700, a chromatographic system
combining size exclusion with anion exchange, failed to elim-
inate impurities under either acidic conditions (Ringer pH 5.6)
or alkaline conditions (Ringer or 50 mMTris-HCl, pH 8.7), as
in both cases, most of the H-1PV was eluted at the cleaning-
in-place step with 1 M salt wash or 1 M NaOH in 30%
isopropanol. Slightly better results were obtained by applying
Table 2 Comparison of H-1PV
recovery and depletion of empty




downstream process from the
same starting material
Method of purification IOD-PBS-VIS-Ringer
gradient
DEAE-Vivaspin® DEAE-HiTrap™






PFU/ml 3.7 ± 0.6E+10 3.5 ± 0.5E+10 3.0 ± 0.3E+09
volume [ml] 1.3 ± 0.5 4.4 ± 0.2 39.1 ± 9.3
PFU/mg protein* 2.1 ± 0.1E+11 6.8 ± 2.5E+11 2.3 ± 0.3E11
Recovery PFU %* 13.1 ± 1.6 41.3 ± 15.5 42.3 ± 2.9
PP-to-GP ratio* 2.8 ± 0.5 1.1 ± 0.3 1.2 ± 0.0
Depletion of protein
impurities %
98.5 ± 0.1 98.3 ± 0.3 96.5 ± 0.5
Depletion of empty
particles %*
85.0 ± 1.3 95.8 ± 5.9 97.8 ± 1.5
Means with standard deviations (n = 2) of infectious titer (PFU/ml), recovery of infectious particles*, specific
activity* (PFU/mg protein), the PP-to-GP ratio*, and depletion of empty particles* and protein impurities. The p
value is ≤0.05 for the features marked with asterisk. For p value calculation, two further IOD-PBS-Vis-Ringer
density gradient purified batches were taken into account
Table 1 Comparison of five
individual chromatography
batches








1 100 26 93 45
2 72 53 74 55
3 52 71 73 28
4 47 100 64 60
5 64 77 58 58
Mean
[n = 5]
67 ± 21 65 ± 28 72 ± 13 49 ± 13
Means with standard deviations for five independent chromatography runs
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H-1PV diluted in Ringer solution (pH 5.6): 17% full particle
recovery in the flow through (data not shown). This is in
disagreement with the column manufacturer’s claim that vi-
ruses and large molecules (Mr > 700 kDa) are collected in the
flow through (GE Healthcare, Application note 29-0983-01
AB). The H-1PV capsid, with a molecular weight of around
6E6 Da, should theoretically pass through the column. The
reason for this failure of Capto Core 700 is unknown and
was not further investigated. Binding studies with H-1PV
have demonstrated that the virus binds to and elutes from both
cation and anion exchangers, but best recoveries were
achieved with AEX chromatography and elution at pH 8.7
(data not shown). We were also able to purify H-1PV on a
strong anion exchange column (QA), with similar full particle
recovery (data not shown), but as no improvement over
DEAE chromatography was observed in terms of recovery
and protein impurity elimination, we decided to continue
working with DEAE. Likewise, as sodium chloride, sodium
acetate, and ammonium acetate in the eluent gave rise to sim-
ilar resolution of the peaks corresponding to empty and full
capsids, sodium chloride was chosen for H-1PV purification
because H-1PV is stable in this salt and because NaCl is pres-
ent in the final formulation.
The fact that the pI difference between full and empty par-
ticles is at least 0.1 pH unit has enabled us to develop a DEAE
purification method. We show that 65% of the empty particles
and 67% of the main impurities can already be eliminated in
the flow through with 0.15 M NaCl, and that 50% of the full
infectious virus particles can be eluted with 0.3M salt. Thanks
to the high stability of H-1PV, the purification can be per-
formed at room temperature (operating temperature
29 ± 0.45 °C). Temperature, flow rate, and impurities influ-
ence the chromatography and should be taken into account for
the reproducibility and robustness of the method (Mihelic
et al. 2003; Acikara 2013).
With the present method and conditions, the H-1PVelution
profile could not be reproduced with the closely related
protoparvovirus minute virus of mice (MVM) (data not
shown), and empty MVM particles could not be separated
from full ones. The method as developed here is thus specific
to H-1PV.
Although the present method offers an H-1PV yield of
nearly 50% from the clarified cell lysate, one should note that
the medium supernatant of the upstream process is still rou-
tinely discarded, amounting to a 30% loss (Leuchs et al.
























Fig. 5 Protein composition and electron microscope images of virus
batches before and after the downstream process. a, b Protein extracts
of virus samples (1.0E10 PP) were analyzed by SDS-PAGE and revealed
by a silver staining or b immunoblotting with αVP antibodies. M
indicates markers constituting the BenchMark™ Protein Ladder, lane 1
indicates virus harvest, lane 2 indicates IOD-PBS-VIS-Ringer, lane 3
indicates DEAE-VivaspinTM-final formulation, and lane 4 indicates
DEAE-HiTrap-final formulation. c, d, e Electron micrographs showing
clarified cell lysate (c), IOD-PBS-VIS-Ringer (d), DEAE-final
formulation (e). Scale bar is 100 nm
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of our method to purify and concentrate H-1PV, clarified me-
dium supernatant from routine production (corresponding to
1/10 of a 10-layer CS production) was purified as described
here. After DEAE purification, total PFU recovery was about
50%, as observed with cell lysate, but the impurity content of
H-1PV purified from culture medium supernatant was still
high. Therefore, a second round of DEAE purification was
performed, yielding ~20% total PFU recovery in a 50th of
the initial volume. Over 99.7% of the protein impurities were
eliminated after the second DEAE purification step, so that the
protein content was the same as for purified cell lysate (data
not shown). Clearly, more optimization and upscaling will be
required to include the medium supernatant in the complete
downstream purification process in order to achieve a higher
overall yield.
For the final formulation, both buffer exchange methods
were suitable, but use of the Vivaspin® tangential flow filtra-
tion system to exchange the buffer and simultaneously con-
centrate the sample to the desired volume is optimal with
negligible loss. Buffer exchange with the HiTrap™ desalting
column leads to sample dilution and thus to a lower infectious
virus titer in the final formulation. Between the two buffer
exchange methods, there is a one-log infectious virus titer
difference in the final formulation (3.5E10 and 3.0E9 PFU/
ml for Vivaspin® and HiTrap™ desalting, respectively).
The final novel downstream process, which achieves the
target virus titer of 1E10 PFU/ml, involves the following
steps: (1) DNase treatment to eliminate host cell DNA, (2)
clarification (0.2 μm followed by 0.1 μm filtration steps),
(3) anion exchange chromatography to eliminate empty parti-
cles and most impurities, (4) a tangential flow filtration for
buffer exchange and concentration, and (5) final formulation
in Visipaque/Ringer solution.
As compared to iodixanol-based ultracentrifugation, use of
this novel purification strategy involving monolith-based
DEAE anion exchange chromatography significantly im-
proves recovery and specific activity, leading to an optimal
PP-to-GP ratio and significant elimination of empty particles
(p values ≤0.05). The performance of the new method is sim-
ilar to that of the ultracentrifugation-based CsCl density gra-
dient method, in terms of the PP-to-GP ratio and PFU per
milligrams of protein (Leuchs et al. 2016). The virus titer of
1E10 PFU/ml is optimal, because the virus particles start to
aggregate at 1E11 PFU/ml (as attested by high variance of the
titer) and because preparations with a virus titer lower
1E8 PFU/ml are unstable over the years (data not shown).
The overall recovery of 40% with our new purification strat-
egy is comparable with or superior to those obtained in other
virus/viral vector productions (Adamson-Small et al. 2016;
Merten et al. 2016).
Upscaling for clinical applications is possible, with the
larger CIM® DEAE monolith columns commercially avail-
able up to 8 l. These could be loadedwith a total of 5E14 PFU,
(corresponding to 1000 10-layer CSs).Monolithic columns do
not lose resolution with scale-up, so there is no need for new
characterization studies. CIM® DEAE monolith columns of-
fer a high binding capacity with high flow rates and low pres-
sure (Mihelic et al. 2000), which could significantly reduce
purification time and costs. Furthermore, these columns can
be used as disposables or for multiple uses and as a single
column or in multicolumn setups. As the limiting loading
capacity of an 8-ml column is 20 mg BSA/ml and as we
Visipaque/Ringer step gradient (VIS-Ringer)
MgCl2, DNase Digestion of non packaged H-1PV and host cell DNA
Elimination of residual host cell proteins (HCP) 
and fetal bovine serum (FBS)




Elimination ofHCP, FBS, and
empty particles










0.2 µm  and 0.1 µm filters
HiTrap™                    Vivaspin®
Desalting column Tangential flow filtration
Fig. 6 Flow diagram of H-1PV downstream purificationmethods, comparing IOD-PBS-VIS-Ringer gradient purification with DEAE-final formulation
methods
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loaded such a column with only ~15 mg total protein (from
cell lysate corresponding to 2.3E8 cells totaling about
5E11 PFU), the column could be loaded with 10 times as
much. Furthermore, the tangential flow filtration is easily
upscalable by using the proven polyethersulfone membrane
with a pore size of 30 kDa. For upscaling, it is nevertheless
necessary to establish the optimal flow rates and pressure.
In summary, we have developed a simple, robust one-step
chromatography-based purification strategy enabling elimina-
tion of empty H-1PV particles and most impurities on the basis
of their isoelectric points. This novel method offers sufficient
recovery and maintains viral infectivity. It will facilitate aseptic
upscaling according to GMP guidelines for clinical applications.
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